Long-term control of node-positive (N1) prostate cancer, the incidence of which is increasing, is obtainable with aggressive treatment, and definitive external beam radiation therapy (EBRT) with long-term androgen deprivation therapy (ADT) is an increasingly preferred option.
Representative in vitro model systems that accurately model response to therapy and allow the identification of new targets are important for improving our treatment of prostate cancer. Here we describe molecular characterization and drug testing in a panel of 20 prostate cancer cell lines.
To prospectively evaluate the performance of a prespecified statistical model based on four kallikrein markers in blood (total prostate-specific antigen [PSA], free PSA, intact PSA, and human kallikrein-related peptidase 2[hK2]), commercially available as the 4Kscore, in predicting Gleason grade group (GG) ≥2 prostate cancer at biopsy in an international multi-center study at three academic medical […]
Data are scarce regarding intravesical maintenance therapy (MT) with the low-dose bacillus Calmette-Guérin (BCG) Tokyo strain. We investigated the efficacy and safety of MT with a half dose of the Tokyo strain for patients following transurethral resection of nonmuscle invasive bladder cancer (NMIBC).
High-risk non-muscle invasive urinary bladder cancer (NMIBC) presents an increased risk of progression and cancer death. To reduce these risks, two different treatments are recommended – BCG or radical cystectomy (RC).
B7-H3 is a member of the B7 family of immune-regulatory ligands and is a costimulatory molecule promoting the T cell response in vitro. We herein investigated the clinical utility of serum soluble B7-H3 (sB7-H3) in patients with non-muscle invasive bladder cancer (NMIBC).
To describe the Agarwal loop ligation technique for management of the distal ureter in laparoscopic radical nephroureterectomy (LNRU) for upper tract urothelial carcinoma (UTUC) and report on long-term oncological outcomes.
(Urotoday.com) The newly formed Global Society of Rare Genitourinary Tumors (GSRGT) held its inaugural meeting, focusing on penile and testicular cancer. The session held Saturday, December 12th focused on testis cancer. In this session, Dr. Aditya Bagrodia presented a quality-of-life and long-term toxicity focussed assessment on the need for treatment de-escalation in advanced disease.
(Urotoday.com) The newly formed Global Society of Rare Genitourinary Tumors (GSRGT) held its inaugural meeting, focusing on penile and testicular cancer. The session held Saturday, December 12th focused on testis cancer. In this session, the organizers convened a “Clinical Trials Corner” in which Dr. Darren Feldman presented an update on the TIGER trial (Alliance A021102 and […]
(Urotoday.com) To provide a context to the keynote lecture by Dr. Andrea Necchi discussing the management of chemotherapy-resistant germ cell tumors at the inaugural Global Society of Rare Genitourinary Tumors virtual summit, Dr. Lucia Nappi provided a commentary discussion of this topic. By way of background, Dr. Nappi notes that 20-30% of patients will relapse after […]
